Intensity Therapeutics, Inc. (Nasdaq: INTS) announced July 15 that it has resumed patient dosing in its INVINCIBLE-4 Study, a Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE